Lumos Logo

ATI’s Lumos Pharma Raises $34 M in Series B Financing

Lumos-logoATI Bio & Health Science portfolio company, Lumos Pharma, a biotechnology company focused on developing therapeutics for orphan diseases, has announced the successful completion of a $34 million Series B financing. Lumos will use the proceeds for clinical trials and commercialization of its lead compound, LUM-001, for the treatment of Creatine Transporter Deficiency (CTD). Funding will also be used to further develop other therapeutics in the company’s pipeline. Deerfield Management Company led the financing, and is joined by new investors Clarus Ventures and Roche Venture Fund, as well as existing investors New Enterprise Associates (NEA), Sante Ventures and Belgian pharmaceutical company, UCB.

Read the full press release here.
Read the Austin Business Journal story here.